Brian E. Lewis MD, MPH, FACPAssistant Professor of Clinical Medicine, Department of Hematology and Medical Oncology, Tulane University School of Medicine, New Orleans, Louisiana
Dr. Brian Lewis is an Assistant Professor of Clinical Medicine in the Department of Hematology and Medical Oncology at Tulane University School of Medicine in New Orleans. He is also the Chair of the Fellowship Advancement Committee of the Hematology and Medical Oncology Fellowship Program at Tulane.
Following his graduation from George Mason University in Fairfax, Virginia, Dr. Lewis enrolled in the Tulane University School of Public Health and, upon completing his MPH degree, entered medical school at Tulane. He completed his medical degree and residency training in internal medicine at Tulane, where he also completed his fellowship in hematology and medical oncology.
Dr. Lewis is a member of several professional societies, including the American Society of Hematology and the American Society of Clinical Oncology. Dr. Lewis is a Fellow of the American College of Physicians.
Assistant Professor of Clinical Medicine, Department of Hematology and Medical Oncology; Chair, Fellowship Advancement Committee, Hematology and Medical Oncology Fellowship Program, Tulane University School of Medicine
MPH: Tulane University School of Public Health, New Orleans, Louisiana
MD: Tulane University School of Medicine
DisclosuresDr. Brian Lewis does not have any financial interests to disclose.
Recent Contributions to PracticeUpdate:
- Platinum-Based Chemotherapy in Patients With Advanced Prostate Cancer With and Without DNA Repair Gene Aberrations
- 2020 Top Stories in Advanced Prostate Cancer: PARP Inhibitors in Advanced Prostate Cancer With DNA Repair Defects
- ASCO 2020: Abstract Recommendations From Dr. Brian Lewis for Advanced Prostate Cancer
- Olaparib for Metastatic Castration-Resistant Prostate Cancer
- ASCO GU 2020: Abstract Recommendations From Dr. Brian Lewis
- Chemotherapy After Prostatectomy for High-Risk Prostate Carcinoma
- 2019 Top Stories in Advanced Prostate Cancer: Cabazitaxel vs Abiraterone or Enzalutamide in Metastatic Prostate Cancer
- ESMO 2019: Recommendations From Dr. Brian Lewis
- Efficacy and Safety of Abiraterone Acetate Plus Prednisone vs Cabazitaxel as a Subsequent Treatment After First-Line Docetaxel in mCRPC
- Ultra-Hypofractionated vs Conventionally Fractionated Radiotherapy for Prostate Cancer